Almac invests in biocatalysis lauding cost and environmental benefits

By Gareth Macdonald and Claire Videau

- Last updated on GMT

Almac invests in biocatalysis lauding cost and environmental benefits
Almac invests $4m in biocatalysis R&D, describing such technologies as the way forward for the cost efficient production of highly chiral APIs and intermediates.

Outsourcing-pharma spoke with Tom Moody, head of Almac’s biocatalysis unit, who explained that the move is part of focus on bringing green manufacturing technologies to the active pharmaceutical ingredient (API) production process.

The investment, Moody continued, will increase Almac’s suite of enzyme panels, process fermentation capabilities as well as its ability to scale up these technologies for its customers.

He also predicted that Almac’s broad service portfolio of chemistry services and API manufacturing will, when combined with the expanded offering, help the firm compete in the increasingly competitive biocatalysis sector.

Related news

Show more

Related products

Solution for challenging antibodies – Planova™ S20N

Solution for challenging antibodies – Planova™ S20N

Content provided by Asahi Kasei Medical Co., Ltd. | 24-Sep-2024 | White Paper

Designed as a next generation cellulose-based virus removal filter, Planova™ S20N has demonstrated robust filtration performance for challenging molecules...

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Follow us

Products

View more

Webinars